Uniform potent activity of the antiproliferative metal chelate trans-bis(resorcylaldoximato)copper(II) against a large panel of human tumor cell lines in vitro

Chemotherapy

Volumn 50, Issue 5, 2004, Pages 229-233

  Elo, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antineoplastic copper(II) compounds; Cancer management; Cell proliferation; Copper chelates; Leukemia; Melanoma; Salicylaldoximates; Trans bis(salicylaldoximato)copper(II); Tumor treatment

Indexed keywords

BIS(RESORCYLALDOXIMATO)COPPER; COPPER DERIVATIVE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BREAST CARCINOMA; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; KIDNEY TUMOR; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FINLAND; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MICE; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 4143124903     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081943     Document Type: Article

References (12)

1. Elo HO, Lumme PO: Antitumor activity of trans-bis(salicylaldoximato) copper(II): A novel antiproliferative metal complex. Cancer Treat Rep 1985;69:1021-1022.
2. Elo H, Lumme P: Antiproliferative activity of derivatives of trans-bis(salicylaldoximato)copper(II) in vitro. Some in vivo properties of the parent compound. Z Naturforsch [C] 1986;41:951-955.
3. Elo H, Lumme P: Trans-bis(salicylaldoximato)copper(II) and its derivatives as antiproliferative and antineoplastic agents: A review. Inorg Chim Acta 1987;136:149-153.
4. Elo H, Sunila I: Unusual organ distribution of chelated copper in rats. Naturwissenschaften 1987;74:245.
5. Koizumi Q, Tanabe S, Nagaba S, Higuchi K, Nakayama N, Saigenji K, Nonaka M, Yago K: A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: Is patient preference a better primary endpoint? Chemotherapy 2003;49:316-323.
6. Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M: Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 2003;65:102-107.
7. Wang E, Johnson WW: The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 2003;49:303-308.
8. Ichiki M, Gohara R, Rikimaru T, Kitajima T, Fujiki R, Shimada A, Aizawa H: Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study. Chemotherapy 2003;49:200-205.
9. Cascinu S, Catalano V, Giordani P, Baldelli AM, Agostinelli R, Catalano G: Gastrointestinal cancer refractory to chemoterapy: A role for octreotide? Chemotherapy 2001;47:127-133.
10. Mukherjee AK: Resorcylaldoxime as an organic reagent. Anal Chim Acta 1955;13:334-339.
11. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd NR: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-4833.
12. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.